

CHIRON CORP  
Form 8-K  
March 02, 2005

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **March 2, 2005**



# Chiron Corporation

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other  
jurisdiction of  
incorporation)

**0-12798**  
(Commission  
File Number)

**94-2754624**  
(IRS Employer  
Identification No.)

**4560 Horton Street, Emeryville, CA**  
(Address of principal executive offices)

**94608**  
(Zip Code)

Registrant's telephone number, including area code **(510) 655-8730**

**N/A**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-



Item 8.01.

## **Other Events**



On March 2, 2005, Chiron Corporation issued a press release announcing its receipt of a notice from the **UK Medicines and Healthcare products Regulatory Agency (MHRA)** that the agency has lifted the license suspension for Chiron's Liverpool manufacturing facility, which produces **FLUVIRIN®** influenza virus vaccine.





A copy of Chiron's press release is attached hereto as Exhibit 99.1.

Item 9.01

## **Financial Statements and Exhibits**



(c) *Exhibits*

99.1 Press release issued on March 2, 2005.

**SIGNATURE**

SIGNATURE



Edgar Filing: CHIRON CORP - Form 8-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Edgar Filing: CHIRON CORP - Form 8-K

**CHIRON CORPORATION**  
(Registrant)

Date: March 2, 2005

By: /s/ Ursula B. Bartels  
Ursula B. Bartels







